MedPath

Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects

Completed
Conditions
Acromegaly
Registration Number
NCT02807233
Lead Sponsor
Ipsen
Brief Summary

The purpose of this study is to evaluate the effectiveness in IGF-1 control of lanreotide Autogel (ATG) 120 mg at extended dosing intervals (EDIs) (\>4 weeks) in subjects with acromegaly in daily clinical practice.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
115
Inclusion Criteria
  • Men or women aged ≥ 18 years
  • Diagnosed with acromegaly
  • Receiving treatment with ATG 120 mg at extended dosing intervals (> 4 weeks) for at least six months before the study visit.
  • Assay data (blood GH and IGF-1 levels) from immediately before the study visit (performed at least six months after starting the treatment) is available.
  • Able to sign the informed consent form for study participation.
Exclusion Criteria
  • Received radiation therapy treatment in the last six months.
  • Active participation in another clinical study.
  • Physical or mental disorders that, in the investigator's opinion, could affect their ability to sign the informed consent form.
  • Pregnancy or breastfeeding for female patients.
  • No data in their medical records on the treatment start date for ATG 120 mg at extended dosing intervals or on changes to the schedule of administration over the last six months.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Percentage of subjects with a normal Insulin-like Growth Factor 1 (IGF-1) level in the assay before the study visit.Day 1
Secondary Outcome Measures
NameTimeMethod
Percentage of subjects treated with lanreotide autogel (ATG) 120 mg for ≥ 6 months with dosing intervals of five, six, seven or eight weeks.Day 1
Percentage of subjects whose dosing regimen has been changed in the six months before the study.Day 1
Preference for self-administered injections or administration in an outpatient clinic by a medical professional.Day 1
Percentage of subjects with Growth hormone (GH) levels ≤ 2.5 ng/mL or ≤ 1 ng/mL in the assay before the study visit.Day 1
EuroQol-5D (EQ-5D) questionnaire in subjects after ≥ 5 months of treatment with ATG 120 mg at extended dosing intervals.Day 1

Total score and score per domain

Variations between theoretical and real treatment compliance for non-medical reasons.Day 1
Acromegaly Quality of Life Questionnaire (AcroQoL) in subjects after ≥ 5 months of treatment with ATG 120 mg at extended dosing intervals.Day 1

Total score and score per domain

Treatment Satisfaction Questionnaire for Medication-9 (TSMQ-9) in subjects treated with ATG 120 mg at extended dosing intervals after ≥ 5 months.Day 1

Total score and score per domain

Trial Locations

Locations (39)

Hospital Univ. Príncipe de Asturias

🇪🇸

Alcalá de Henares, Spain

Hospital Univ. Nuestra Sra. Candelaria

🇪🇸

Santa Cruz, Tenerife, Spain

Complejo Hospitalario Univ. A Coruña

🇪🇸

A Coruña, Spain

Hospital General Univ. de Alicante

🇪🇸

Alicante, Spain

Hospital Univ. La Ribera

🇪🇸

Alzira, Spain

Hospital Infanta Cristina

🇪🇸

Badajoz, Spain

Hospital Cruces

🇪🇸

Barakaldo, Spain

Hospital Ciudad Real

🇪🇸

Ciudad Real, Spain

Hospital Puerta del Mar

🇪🇸

Cádiz, Spain

Hospital Reina Sofía

🇪🇸

Córdoba, Spain

Hospital de Getafe

🇪🇸

Getafe, Spain

Hospital Univ. Girona Dr. Josep Trueta

🇪🇸

Girona, Spain

Hospital Arnau de Vilanova

🇪🇸

Lleida, Spain

Hospital de Jaén

🇪🇸

Jaén, Spain

Hospital Bellvitge

🇪🇸

Hospitalet de Llobregat, Spain

Hospital Univ. León

🇪🇸

León, Spain

Hospital La Princesa

🇪🇸

Madrid, Spain

Hospital Gregorio Marañón

🇪🇸

Madrid, Spain

Hospital Univ. Central de Asturias

🇪🇸

Oviedo, Spain

Hospital La Paz

🇪🇸

Madrid, Spain

Hospital Univv. La Paz

🇪🇸

Madrid, Spain

Hospital Civil de Málaga

🇪🇸

Málaga, Spain

Hospital Puerta del Hierro

🇪🇸

Madrid, Spain

Hospital Virgen de la Victoria

🇪🇸

Málaga, Spain

Corporacio Sanitaria Parc Tauli

🇪🇸

Sabadell, Spain

Hospital Univ. Son Espases

🇪🇸

Palma, Spain

Hospital Univ. Alava

🇪🇸

Terrassa, Spain

Hospital Infanta Sofía

🇪🇸

San Sebastian de los Reyes, Spain

Hospital Clínico Univ. Santiago

🇪🇸

Santiago de Compostela, Spain

Hospital Virgen del Rocío

🇪🇸

Sevilla, Spain

Hospital Univ. Mutua de Terrassa

🇪🇸

Terrassa, Spain

Hospital Clínico de Valencia

🇪🇸

Valencia, Spain

Hospital Obispo Polanco

🇪🇸

Teruel, Spain

Hospital Virgen de la Salud

🇪🇸

Toledo, Spain

Hospital Univ. La Fe

🇪🇸

Valencia, Spain

Hospital Clínico Univ. Valladolid

🇪🇸

Valladolid, Spain

Hospital Miguel Servet

🇪🇸

Zaragoza, Spain

Centro Hospitalar Sao Jöao

🇵🇹

Porto, Portugal

Hospital de Santa Maria

🇵🇹

Lisboa, Portugal

© Copyright 2025. All Rights Reserved by MedPath